Premark Pharma GmbH

Premark Pharma GmbH develops and commercialises topical treatments for inflammatory diseases of the skin, eye, mucosae and mucocutaneous surfaces. Its lead ophthalmic assets include pimecrolimus formulations such as PMP2207 (an ointment for blepharitis) and PMP1606 (a liquid suspension for dry eye), with Phase 3 programmes planned and regulatory approvals sought in the EU and US.